IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis

ConclusionsIL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.
Source: Cardiovascular Research - Category: Cardiology Source Type: research

Related Links:

My mind is racing because I’ve seen two aortic dissections in the last week and I feel like I could have easily missed them had I been in a rush and not prodded during the history. Makes me cringe thinking about it. First one was a 69 year old with hypertension. Sudden onset of chest pain when watching TV. With no other symptoms at all. The thing that tipped me off is he didn’t want to move. Moving hurt his chest. Breathing hurt his chest. Me pushing on his chest made him wince. Just didn’t... How did your aortic dissection cases present?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Emergency Medicine Source Type: forums
ConclusionsPatients with CMS were more likely to present with increased comorbidities. Patients with CMS undergoing CABG were at risk for worse short ‐term secondary postoperative outcomes and reduced long‐term survival. The data supports the need for further investigation for risk reduction surrounding operative revascularization.
Source: Journal of Cardiac Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: ORIGINAL ARTICLE Source Type: research
This is the latest in a series of yearly posts in which I suggest areas of development for biotech startups I'd like to see actively developed as a part of the longevity industry in the near future. Today, this year, is a good time to be starting a company focused on the production of a novel therapeutic approach to intervening in the aging process. There is a great deal of funding for seed stage investment, and many compelling projects lacking champions, yet to be carried forward from academia into preclinical development. Numerous scientific and industry crossover conferences are now held every year, at which it is possi...
Source: Fight Aging! - Category: Research Authors: Tags: Investment Source Type: blogs
By JESSICA DaMASSA, WTF HEALTH On the heels of a $40M Series B funding round led by Bayer, One Drop CEO Jeff Dachis stops by to hit the highlights about how the digital health platform is touching the lives of 1.6 million users in nearly 200 countries. Focused on chronic conditions like diabetes, pre-diabetes, hypertension, etc. One Drop is unique in the BIG direct-to-consumer business they’ve built through partnerships with Walmart and Apple stores. While Jeff says their growth capital will go toward expanding their heath plan and employer business, there’s also room for growth with Bayer, which could help ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Tech Health Technology Jessica DaMassa WTF Health chronic disease Diabetes Frontiers Health Hypertension Jeff Dachis One Drop pre-diabetes Source Type: blogs
Condition:   2019-nCoV Intervention:   Sponsor:   Chongqing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Thromboembolic Pulmonary Hypertension Interventions:   Drug: Macitentan;   Drug: Placebo Sponsor:   Actelion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
HIGH blood pressure can quietly cause major damage to the body over the years before any real symptoms develop. Noticing a sign in your voice could be an early warning of the deadly condition. What is it?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Condition:   Chronic Thromboembolic Pulmonary Hypertension Interventions:   Drug: Macitentan;   Drug: Placebo Sponsor:   Actelion Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   2019-nCoV Intervention:   Sponsor:   Chongqing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Columbia University Irving Medical Center) Patients taking the recommended diuretic for hypertension had nearly three times the risk of potentially serious side effects, according to a new study from researchers at Columbia University.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cardiology | Cardiovascular | Chemistry | Heart | Hypertension | Study